Gout is increasing in both incidence and severity. Treatment adherence issues on allopurinol alone and resistant gout lead to failed target serum uric acid concentration. There are new and emerging agents, including xanthine oxidase inhibitors, uricosuric agents, uricase agents, and interleukin 1 inhibitors—drugs that can provide alternatives to allopurinol alone. It is incumbent upon managed care pharmacists to be knowledgeable of the comparative efficacy and costs of various medication protocols now available.
These didactic, interactive presentations will update participants with cost-effective analysis, as well as pharmacologic and lifestyle management strategies, thereby minimizing costs and maximizing therapeutic outcomes.
This interactive activity has been designed to enhance pharmacists’ understanding of the latest management strategies for gout, thereby maximizing therapeutic outcomes
This activity is designed for pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
- DISCUSS the comorbidities associated with gout including increased cardiovascular and metabolic morbidity and mortality from inadequately treated disease.
- FORMULATE strategies to promote patient adherence and optimize the utilization of medications for gout.
- IDENTIFY the role of new therapies for the management of gout and their potential to affect cost:benefit ratios.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 1.5 contact hour credit (0.15 CEU) and will be available at the completion of the activity. Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination 2 more times. The statement will be available online immediately following successful completion of the activity. ACPE Program #0064-0000-12-206-H01-P.
Beginning 2012 your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website (www.nabp.net/programs/cpe-monitor/cpe-monitor-service) or contact NABP Customer Service: email@example.com or telephone 847-391-4406.
The estimated time to complete this educational activity: 1.5 hours.
Release date: June 15, 2012; Expiration date: June 15, 2013.
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The faculty reported the following:
Glen E. Farr, PharmD (Chair)
Professor of Clinical Pharmacy and Associate Dean
University of Tennessee College of Pharmacy
Dr Farr reports serving on the speakers’ bureau for Abbott Pharmaceuticals.
Brandon Bellows, PharmD
Health Economics & Outcomes Research Fellow
Pharmacotherapy Outcomes Research Center
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, Utah
Dr Bellows reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Diana I. Brixner, RPh, PhD
Professor and Chair
Executive Director, Pharmacotherapy Outcomes Research Center
The Department of Pharmacotherapy
The University of Utah College of Pharmacy
Salt Lake City, Utah
Dr Brixner reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Dana A. Brown, PharmD, BCPS
Assistant Dean for Academics, Associate Professor
Palm Beach Atlantic University
Lloyd L. Gregory School of Pharmacy
West Palm Beach, Florida
Dr Brown reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
H. Ralph Schumacher, MD
Professor of Medicine
University of Pennsylvania and VA Medical Center
Dr Schumacher reports serving as a consultant for Ardea Biosciences, Metabolex, Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron Pharmaceuticals, Inc, Savient Pharmaceuticals, Inc, and Takeda Pharmaceutical Company Limited.
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at firstname.lastname@example.org. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
There is no fee for this educational activity.
Please complete the pre-test; view the following presentation and respond to the interactive questions; and complete the post-test and evaluation to receive CPE credit for this activity.
- Gout: An Old Disease with a New Resurgence
- Gout and Hyperuricemia: More than Just Pain in the Big Toe
- Adherence: The Key to Success for Gout Treatment
- Designing a Treatment Regimen for the Patient with Gout
- Conclusion/Closing Remarks/Q&A
What you are about to see is a previously recorded live meeting. Please note that only “home study” credit will be awarded for participating in this archived presentation. No “live” credits are available.